Vaxart Inc (VXRT) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Vaxart Inc   (VXRT)


Vaxart Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Vaxart Inc's ROI in the second quarter of 2026?
Vaxart Inc achieved a return on average invested assets (ROI) of 46.17 % in its second quarter of 2026, this is above VXRT's average return on investment of -42.62%.
Vaxart Inc invested over the 12 months ending in its second quarter of 2026 $84 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 31 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 89, from total ROI ranking in the first quarter of 2026 at 90.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 24.7 % -9.83 % -26.64 % -34.28 % -22.3 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 92 103 99 40 46
Return On Investment (TTM) 46.17 % 51.45 % 26.63 % -91.58 % -84.51 %
VXRT's Overall Ranking # 89 # 90 # 147 # 3539 # 3505
Seq. Investment Change TTM 15.9 % 17.6 % 10.75 % -17.39 % -16.19 %
Seq. Net Income Change TTM 4.02 % 127.21 % - - -
Net Income (TTM) in Millions 39 37 16 -51 -57

VXRT Company Profile >> Back to VXRT Roi Comparisons >> See Annual VXRT Return On Investment



Return On Investment VXRT's Ranking
Within: No.
Industry # 7
Sector # 32
Overall # 89

Return On Investment Statistics
High Average Low
51.45 %
-42.62 %
-94.9 %
(Mar 31 2026)   (Jun 30 2017)







Financial Statements
Vaxart Inc's II. Quarter Investments $ 92 Millions VXRT's Balance sheet
Vaxart Inc's II. Quarter Income $ -13 Millions Quarterly VXRT's Income Statement
VXRT's Income by Division See VXRT's Income by Division


VXRT Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 99 76 78 136 210
Y / Y Investment Growth 31.54 % -3.32 % -42.54 % -35.39 % 49.4 %
Net Income in Millions 16 -67 -82 -108 -70
Y / Y Net Income Growth - - - - -
Annual Return On Investment 16.44 % -88.66 % -105.58 % -79.28 % -33.5 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 16.44 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VXRT's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VXRT's Competitors
Subscribers only: Roi for Vaxart Inc's Suppliers
Subscribers only: Return On Investment for VXRT's Customers

Other Ratios
VXRT's Roa VXRT's Inventory Turnover Ratio VXRT's Growth Rates VXRT's Dividend Statistics
VXRT's Profitability Ratios VXRT's Asset Turnover Ratio VXRT's Dividend Growth
VXRT's Roe VXRT's Valuation Ratios VXRT's Financial Strength Ratios VXRT's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %

Date modified: 2026-09-08T22:50:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.